Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Net Income: 2023-2024

Historic Net Income for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$14.6 million.

  • Contineum Therapeutics' Net Income fell 87.48% to -$14.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$42.3 million, marking a year-over-year decrease of 285.94%. This contributed to the annual value of -$42.3 million for FY2024, which is 285.99% down from last year.
  • Latest data reveals that Contineum Therapeutics reported Net Income of -$14.6 million as of Q4 2024, which was down 41.86% from -$10.3 million recorded in Q3 2024.
  • In the past 5 years, Contineum Therapeutics' Net Income ranged from a high of $41.6 million in Q2 2023 and a low of -$14.6 million during Q4 2024.
  • In the last 2 years, Contineum Therapeutics' Net Income had a median value of -$8.1 million in 2023 and averaged -$2.4 million.
  • Data for Contineum Therapeutics' Net Income shows a maximum YoY slumped of 121.67% (in 2024) over the last 5 years.
  • Contineum Therapeutics' Net Income (Quarterly) stood at -$7.8 million in 2023, then crashed by 87.48% to -$14.6 million in 2024.
  • Its Net Income was -$14.6 million in Q4 2024, compared to -$10.3 million in Q3 2024 and -$9.0 million in Q2 2024.